Skip to main content
Fig. 5 | Antimicrobial Resistance & Infection Control

Fig. 5

From: Carbapenem-resistant Enterobacterales sepsis following endoscopic retrograde cholangiopancreatography: risk factors for 30-day all-cause mortality and the development of a nomogram based on a retrospective cohort

Fig. 5

Visual representation of the consequences of different antimicrobial therapies shown through Kaplan‒Meier curves. (A) There was no difference in 30-day mortality among patients who were given empirical carbapenems. (B-C) Patients who received empirical tigecycline had a negative prognosis within 30 days, whereas those who received empirical polymyxin B had a survival benefit within the same time frame. (D) There was no variation in the 30-day mortality rate among patients who received combination therapy with carbapenem. (E) Individuals who received combination therapy involving tigecycline experienced an unfavorable prognosis within a 30-day period. (F) On the other hand, individuals who received combination therapy involving polymyxin B experienced a survival advantage for a period of 30 days

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us